FDA Announces ‘Green List’ of Foreign GLP-1 Ingredient Manufacturers

Sen. Tom Cotton (R-Ark.) applauds the FDA for taking action, noting that China has flooded the United States with counterfeit drugs.

A U.S. Food and Drug Administration (FDA) sign is seen outside the agency's White Oak campus in Silver Spring, Md., on July 17, 2025. Issam Ahmed/AFP via Getty Images

The Food and Drug Administration recently announced new measures to prevent the import of dangerous foreign counterfeits of GLP-1 drug ingredients, which are being used to make unapproved compound drugs targeting individuals seeking weight loss medication.

On Sept. 5, the FDA announced the creation of a “green list” import alert for GLP-1 active pharmaceutical ingredients (APIs), according to a statement. Only GLP-1 APIs manufactured at facilities that the health agency has inspected or evaluated and found compliant with its rigorous standards will make the list, the FDA added.